1. Home
  2. Diagnostics
  3. Intestinal Inflammation
  4. IBD-SCAN® – T5009

[col_23]
A quantitative ELISA for the detection of fecal lactoferrin.

 

[image source=”https://www.techlab.com/wp-content/uploads/2013/06/t5009.jpg” alt=”IBD-SCAN” align=”right” border=”true”]

The IBD-SCAN® test is a quantitative ELISA for measuring concentrations of fecal lactoferrin, a marker of fecal leukocytes. An elevated level is an indicator of intestinal inflammation.

The test can be used as an in vitro diagnostic aid to distinguish patients with active inflammatory bowel disease (IBD) from those with noninflammatory irritable bowel syndrome (IBS). In addition, the test can be used to assess when an IBD patient is in confirmed remission and has responded to treatment.

Further Information

Package Insert (PDF) Issued 4/08

CPT Codes (PDF) Issued 02/2023

Material Safety Data Sheet (PDF) Issued 10/13

Declaration of Conformity (PDF) Issued 08/14

Poster Presentation (PDF)
Ribotype 027 is Associated with Increased Lactoferrin and Toxin in Patients with Clinically Defined C. difficile Disease
American Society of Microbiology meeting, May 2011, New Orleans, LA

Poster Presentation (PDF)
Evaluation of Fecal Lactoferrin, CRP and Clinical Activity Indices for Assessing the Presence of Intestinal Inflammation in IBD and IBS Patients Classified by Ileocolonoscopy

Poster Presentation (PDF)
Comparison of CRP, Clinical Activity Indices and Fecal Lactoferrin with Disease Status in Ileocolonoscopy of Patients with IBD and IBS
Digestive Disease Week, May 2006, Los Angeles, CA

Poster Presentation (PDF)
A Comparison Among Four Neutrophil-Derived Proteins in Feces as Indicator of Disease Activity in Ulcerative Colitis
Digestive Disease Week, May 2004, New Orleans, LA

Poster Presentation (PDF)
Serial Fecal Lactoferrin Measurements are Useful in the Interval Assessment of Patients with Active and Inactive Inflammatory Bowel Disease
Digestive Disease Week, May 2004, New Orleans, LA

Poster Presentation (PDF)
Fecal Lactoferrin: Sensitive Marker for Monitoring Pediatric Patients with Inflammatory Bowel Disease (IBD)
Digestive Disease Week, May 2003, Orlando, FL

[/col_23]

[col_14_last]

Features

[arrowlist]

  • Quantitative assay to determine the presence of intestinal inflammation
  • Prediluted standards
  • Accurate measurement of both solid and liquid fecal samples using novel pipet design

[/arrowlist]

This product is available exclusively through our global distributor, Alere.

[/col_14_last]